Leukocyte depletion for safe blood transfusion.
Leukocytes have ability to distinguish between self cells (body own cells) and foreign (allogenic) cells on the basis of human leukocyte antigen (HLA) proteins that are present on the cell membrane and are effectively unique to a person. During allogenic blood transfusion a person receives large number of allogenic donor leukocytes and these are recognized as foreign cells by the recipient immune system which leads to several adverse reactions. To avoid such leukocyte-mediated adverse reactions leukodepleted blood transfusion is required. Leukocytes can be separated on the basis of size, dielectric properties, by affinity separation, freeze-thawing and centrifugation but all these methods are time consuming and costly. Filtration is another method for leukocyte depletion that is comparatively less expensive and more efficient as it gives more than 90% leukodepletion of blood along with minimal cell loss. However, present filtration procedures also have some limitations as they work efficiently with blood components but not with whole blood and show non-specific adhesion of large number of platelets and red blood cells along with leukocytes. All the currently available filters are costly, which has been a major reason for their limited application. Therefore, demand for a more efficient and cost-effective filter is high in medical community and scientists are attenpting to improve the efficiency of currently available filters. The present review gives an overview of the significance of leukodepleted blood transfusion and focuses on different methods for leukocyte depletion and challenges involved in all these technologies.
Singh
Shikha
S
Department of Biological Sciences and Bioengineering, Indian Institute of Technology Kanpur, India.
Kumar
Ashok
A
D001781:Blood Component Removal / Q000295:instrumentation*; D001792:Blood Platelets / Q000166:cytology; D001803:Blood Transfusion / Q000295:instrumentation* / Q000379:methods*; D002469:Cell Separation / Q000295:instrumentation*; D002498:Centrifugation; D007562:Creutzfeldt-Jakob Syndrome / Q000635:transmission; D004867:Equipment Design; D005374:Filtration / Q000295:instrumentation*; D006680:HLA Antigens / Q000737:chemistry; D006801:Humans; D007962:Leukocytes / Q000166:cytology*; D015427:Reperfusion Injury; D012449:Safety; D014780:Viruses / Q000378:metabolism
D006680:HLA Antigens